Dyne Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Dyne Therapeutics, Inc. (DYN) holds an ST Score of 46.2 out of 100 (C+), with its strongest factor being Valuation (A-) and its weakest Growth (D-). Analysts rate DYN Buy across 14 ratings with a $33.71 average price target (+1.0% vs the current $17.12).
- Strongest
- ValuationA-
- Weakest
- GrowthD-
All factor grades
- ValuationA-
- Financial StrengthA-
- ForecastB
- ProfitabilityC
- MomentumC
- GrowthD-
- Piotroski2/9
Contact
DYN stock: frequently asked questions
What is DYN's ST Score?
Dyne Therapeutics, Inc. (DYN) has an ST Score of 46.2 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is DYN a buy, sell, or hold?
Wall Street's consensus rating on DYN is Buy based on 14 analyst ratings. Our own ST Score grades it C+ (46.2/100). This is data, not investment advice — always do your own research.
What is DYN's valuation grade?
Dyne Therapeutics, Inc. (DYN) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is DYN's growth grade?
Dyne Therapeutics, Inc. (DYN) earns a growth grade of D-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is DYN's profitability grade?
Dyne Therapeutics, Inc. (DYN) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is DYN's financial strength grade?
Dyne Therapeutics, Inc. (DYN) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for DYN?
The average analyst price target for Dyne Therapeutics, Inc. (DYN) is $33.71 from 14 analysts, which is +1.0% versus the recent price of $17.12.
What is DYN's Piotroski score?
Dyne Therapeutics, Inc. (DYN) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.